Aug. 9 at 9:13 PM
$SLS Trial was Enrolling during the Teeth of the COVID Pandemic. A.
and B.
The FINAL RESULTS are phenomenal.
The Dr's Co-Authoring the Paper, which includes Merck Dr. Julie Cohen, Concluded a Phase 3 trial is warranted. Which in MED SPEAK is extremely bullish.
- furthermore, the dr's explain that Gps + Key/any CPI will work Even Better in Earlier Patient Settings, prior to the advanced End stage like this trial, where GPS + key MOS of 18.4 months is Better than Elahere
$IMGN that was bought for 10.1B based on an MOS of just 16.46 Months in the same Setting.
Similarly,
$CORT just published p3 data, its drug relacoriant? + Intensive Chemo achieved an MOS of 16.5 months in this PROC setting - its Market Value Jumped
$4B the day of the announcement. and GPS + Key
$MRK is Better.
